Patents by Inventor Richard A. Metz

Richard A. Metz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11160224
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: November 2, 2021
    Assignee: CIBUS US LLC
    Inventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
  • Publication number: 20180355327
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 13, 2018
    Applicant: CIBUS US LLC
    Inventors: PETER R. BEETHAM, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
  • Patent number: 10035991
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: July 31, 2018
    Assignee: CIBUS US LLC
    Inventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
  • Patent number: 8436151
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: May 7, 2013
    Assignee: Lankenau Institute for Medical Research
    Inventors: George C. Prendergast, Richard Metz
  • Publication number: 20120090044
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Application
    Filed: November 4, 2011
    Publication date: April 12, 2012
    Inventors: George C. Prendergast, Richard Metz
  • Patent number: 8058416
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: November 15, 2011
    Assignee: Lankenau Institute for Medical Research
    Inventors: George C. Prendergast, Richard Metz
  • Publication number: 20090158451
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Application
    Filed: November 18, 2008
    Publication date: June 18, 2009
    Inventors: George C. Prendergast, Richard Metz
  • Publication number: 20080256668
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphoniorethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phophonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Application
    Filed: November 16, 2007
    Publication date: October 16, 2008
    Inventors: PETER R. BEETHAM, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
  • Patent number: 7060500
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2?-O-methyl ribonucleotides.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 13, 2006
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Patent number: 6929917
    Abstract: The invention concerns a new method of detecting a rare product of a directed genetic alteration of a cultured cell. The method is applicable to any method of making the alteration provided that a pair of closely linked alterations can be made. The method consists of sequentially using allele specific polymerase chain reaction (PCR) to preferentially amplify sequences containing one of the two linked alterations coupled with a second method that detects the second change in the PCR product. The second method can be restriction digestion, traditional sequencing or pyro-sequencing. Experiments indicate that alterations as rare as one correctly altered copy in 10,000 cells can be detected.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: August 16, 2005
    Assignee: PreGentis
    Inventors: Richard Metz, Mike DiCola, R. Michael Blaese
  • Publication number: 20050177899
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Application
    Filed: February 4, 2005
    Publication date: August 11, 2005
    Inventors: Peter Beetham, Patricia Avissar, Keith Walker, Richard Metz
  • Patent number: 6870075
    Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: March 22, 2005
    Assignee: Valigen (US), Inc.
    Inventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
  • Publication number: 20040096832
    Abstract: The invention concerns a new method of detecting a rare product of a directed genetic alteration of a cultured cell. The method is applicable to any method of making the alteration provided that a pair of closely linked alterations can be made. The method consists of sequentially using allele specific polymerase chain reaction (PCR) to preferentially amplify sequences containing one of the two linked alterations coupled with a second method that detects the second change in the PCR product. The second method can be restriction digestion, traditional sequencing or pyro-sequencing. Experiments indicate that alterations as rare as one correctly altered copy in 10,000 cells can be detected.
    Type: Application
    Filed: November 18, 2002
    Publication date: May 20, 2004
    Inventors: Richard Metz, Mike DiCola, R. Michael Blaese
  • Publication number: 20040023392
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.
    Type: Application
    Filed: November 12, 2002
    Publication date: February 5, 2004
    Applicant: ValiGen (US), Inc.
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Publication number: 20030229910
    Abstract: A method for generating cattle resistant to Bovine Spongioform Encephalopathy through targeted alterations in the PrP gene is disclosed. The PrP gene of a cultured cells is altered to prevent its translation or to encode a dominant disease-resistant form of the protein, and the nucleus of the altered cell is used to clone a founder animal. In one embodiment, a single-stranded DNA fragment containing the alteration is used in single-stranded short fragment homologous replacement to alter the PrP gene.
    Type: Application
    Filed: April 17, 2003
    Publication date: December 11, 2003
    Inventors: Richard Metz, R. Michael Blaese
  • Patent number: 6586184
    Abstract: The invention is based on the discovery that recombinagenic oligonucleobases are active in prokaryotic cells that contain a strand transfer activity (RecA) and mismatch repair activity (MutS). Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in prokaryotic cells than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacing the tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2′-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase and removing the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern the use of Duplex Mutational Vectors in prokaryotic cells.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: July 1, 2003
    Assignee: ValiGen (U.S.), Inc.
    Inventors: Ramesh Kumar, Richard A. Metz
  • Publication number: 20020184043
    Abstract: A method for management of business metrics using a system including a server and at least one user accessible device communicative with the server, the server having a database and a web interface, the method providing user with a web interface configurable to a template accommodating business metrics data by the user. An apparatus comprising a computer, a server configured with a database enabled for storing and retrieving a web interface, the server additionally configured to upload and store business metrics data in a database, and a network communicative with the server and a user device connected to the network.
    Type: Application
    Filed: June 4, 2001
    Publication date: December 5, 2002
    Inventors: Egidio Lavorgna, Ramesh Thuravil, Richard Metz
  • Patent number: 6479292
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: November 12, 2002
    Assignee: ValiGen (US), Inc.
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Publication number: 20020151072
    Abstract: The invention is based on the discovery that recombinagenic oligonucleobases are active in prokaryotic cells that contain a strand transfer activity (RecA) and mismatch repair activity (MutS). Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in prokaryotic cells than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacing the tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2′-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase and removing the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern the use of Duplex Mutational Vectors in prokaryotic cells.
    Type: Application
    Filed: April 3, 2001
    Publication date: October 17, 2002
    Applicant: ValiGen (U.S), Inc.
    Inventors: Ramesh Kumar, Richard A. Metz
  • Patent number: RE49708
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 24, 2023
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: George C. Prendergast, Richard Metz